OFF-X release information

Latest enhancements

  • Enhanced export functionalities
  • Customized notifications
  • Comparative drug safety views with frequency values
  • Contextual FAQs
  • New classification of CAR-T cell therapies by viral vector

Planned enhancements

  • Customized content in the Home page (April 2024)
  • New exports (April 2024)
  • Updated Real-World Evidence Analysis dashboard (April 2024)
  • OFF-X Knowledge Base (April 2024)
  • Comprehensive curation of the full archive of drug approval packages by the EMA and UK’s MHRA (April 2024)
  • Final launch of the re-platformed OFF-X app and shutdown of the current user-interface (June 2024)
  • Enhanced Analytics (June 2024)
  • Anticipate safety liabilities of novel targets based on upstream/downstream genes in their metabolic pathways (June 2024)
  • Enhanced Drug Combinations area (June 2024)

Learn more about our latest releases

February 21, 2024, Release Notes

Enhanced export functionalities; Set up customized notifications; Comparative drug safety views with frequency values; Contextual FAQs; Classification of CAR-T cell therapies based on viral vector.

Go to full release notes

December 13 2023 Release Notes

Beta release of the new OFF-X platform

Go to full release notes

November 15 2023 Release Notes

Update and improvement of the OFF-X Target/Class algorithm; Comprehensive curation of the full archive of FDA labels

Go to full release notes

June 14 2023 Release Notes

New clinical trial metadata and filters; seamless navigation to Cortellis Trials Intelligence; improvement of the OFF-X Drug Score; all FDA labels since 1965.

Go to full release notes

May 10 2023 Release Notes

Enhanced coverage of discontinued drugs; New content added to Secondary Pharmacology Panels; Updated Safety Maps; 200 FDA labels approved between 1980-1999; Updated links to ChEMBL from drug records.

Go to full release notes

February 22 2023 Release Notes

Viral vector-centric safety assessment of gene therapies; Updated and enhanced PubMed text mining data to complement curated safety alerts; Completion of the manual curation of the archive of PMDA drug approval packages.

Go to full release notes

OFF-X December 21 2022 Release Notes

Causality metadata & filter to identify treatment-related adverse events; Frequencies of adverse events; Safety data of vaccines approved by the FDA and EMA; Enhancement of the Secondary Pharmacology Panels tool.

Go to full release notes

OFF-X November 16 2022 Release Notes

New analytics page grouping the analytic tools by use case; New header, sub-header and search bar; Enhancement of the Drug Label Analyzer tool; Text mining results from FDA Summary Basis of Approval documents shown by default in all views.

Go to full release notes

OFF-X October 5 2022 Release Notes

Links to clinicaltrials.gov; Clinical trial record to access different publications covering the same clinical study; Improvement of the OFF-X Drug Score; Webinars and recorded training sessions

Go to full release notes

OFF-X September 7 2022 Release Notes

Further integration of the RWE Analysis Dashboard in pharmacovigilance use cases; Shortcut to FDA Summary Basis of Approval documents; Expanded drug mapping between OFF-X and Cortellis Competitive Intelligence

Go to full release notes

OFF-X July 27 2022 Release Notes

Enhancement of the Safety Alerts section for the assessment of PV signals, including SMQ navigation and links to analytics; Enhanced SMQ navigation in the RWE Analysis Dashboard; Expansion of the retrospective coverage of FDA SBA documents.

Go to full release notes

OFF-X June 29 2022 Release Notes

Label changes and new adverse events notifications added to Keep Me Posted alerts; OFF-X Drug and Target/Class Score added to the Safety Alerts section; Enhanced filtering functionalities; Retrospective analysis of PMDA approval packages.

Go to full release notes

OFF-X May 24 2022 Release Notes

Further integration of safety data extracted from FDA Summary Basis of Approvals (SBA); Enhanced navigation of the FDA SBA text mining results; New filter in the RWE dashboard to exclude adverse events reported in FDA SBAs; Short-cut to the safety alerts of drug’s secondary targets; Seamless navigation between OFF-X and other Clarivate products.

Go to full release notes

OFF-X April 5 2022 Release Notes

Customization of the alerts sent to the user’s mailbox; New analytics to allow the comparison of the safety profile of drugs and their targets; Integration of safety data extracted from FDA Summary Basis of Approvals via text mining methods.

Go to full release notes

OFF-X February 2 2022 Release Notes

New Comparative Target Safety Evidence tool to easily assess the safety liabilities associated with the pharmacological modulation of different targets

Go to full release notes

OFF-X December 16 2021 Release Notes

Usability enhancements with new filter options to quickly identify the adverse events of interest; Comparative Drug Safety Evidence and Master view heatmaps enhancements; FAERS and JADER content update.

Go to full release notes

November 9 2021 Release Notes

Comparative Drug Safety Evidence view enhancements and content updates (Safety Maps and Real World Evidence dashboards)

Go to full release notes

September 21 2021 Release Notes

New Real World Evidence analysis dashboard including reports from FAERS and JADER databases to validate and analyze potential pharmacovigilance signals.

Go to full release notes